Medicare: Faster Access to Breakthrough Medical Devices
A house committee must act next: committee consideration.
The bill has strong bipartisan support and addresses a clear problem for patients, but it involves new spending and changes to Medicare that may face budget hurdles.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Smaller medical device makers that get FDA priority review could see faster Medicare payment for their products, helping revenue, but they must still meet strict criteria and face possible denial or billing audits if usage patterns look unusual, adding compliance costs.
“The Secretary may conduct a review of the medical necessity and reasonableness of a breakthrough device furnished by a provider of service or supplier that the Secretary determines has an aberrant billing pattern”
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Committee Consideration and Mark-up Session Held
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
The House Ways & Means Committee voted 38 to 3 to approve the Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343). The bill would ensure prompt coverage of breakthrough devices under Medicare by introducing a transitional coverage period of four years. The legislation aims to bridge the gap between FDA approval and Medicare reimbursement, allowing seniors immediate access to innovative technologies while the government makes long-term coverage determinations.
The House Ways and Means Committee advanced legislation that would provide four years of transitional Medicare coverage for breakthrough medical devices. The Ensuring Patient Access to Critical Breakthrough Products Act seeks to codify a pathway for immediate reimbursement following FDA authorization, addressing industry complaints that the current process takes an average of five years to complete.
The Ensuring Patient Access to Critical Breakthrough Products Act has cleared the House Ways & Means Committee, promising to guarantee four years of Medicare coverage for technologies designated as breakthrough by the FDA. Supporters argue the bill will modernize Medicare by aligning coverage timelines with FDA approvals, ensuring that seniors do not have to wait years for life-saving diagnostic and treatment tools.
No votes or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Ensuring Patient Access to Critical Breakthrough Products Act
Analysis generated by AI. Always verify with official sources.